Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Hysterical disorders in patients with hematological diseases].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2025
Same author

Mutations in human cytymegalovirus (Orthoherpesviridae: Herpesvirales: Cytomegalovirus: Cytomegalovirus humanbeta 5) UL97 gene lead to increase in viremia duration and poor antiviral response in recipients of allogeneic hematopoietic stem cells.

Voprosy virusologii·2024
Same author

[Therapy of mental disorders in patients with hematological malignancies].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2024
Same author

[Adherence to treatment of hematological malignancies patients with anxiety and depression].

Terapevticheskii arkhiv·2023
Same author

[Psychopharmacotherapy of mental disorders in hematological patients: security concerns].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2023
Same author

[Resistance to antiviral drugs in human viruses from the subfamily <i>Betaherpesvirinae</i>].

Voprosy virusologii·2022

Related Experiment Video

Updated: Aug 18, 2025

Humanized NOD/SCID/IL2r&#947;null (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

15.8K

LABORATORY DIAGNOSTICS OF ACTIVE AND LATENT HHV 6-INFECTION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES.

N G Yaroslavtseva1, D S Tikhomirov1, T Y Romanova1

  • 1National Medical Research Center of Hematology.

Voprosy Virusologii
|December 10, 2022
PubMed
Summary

Latent Human Herpes Virus type 6 (HHV 6) infection is common in hematological malignancy patients. Active HHV 6 infection is usually a monoinfection, with HCMV as the most frequent co-infectant, and is associated with mild leukopenia.

Keywords:
Human herpes virus type 6laboratory diagnosicsviral integration

More Related Videos

Measurement of &#947;HV68 Infection in Mice
13:22

Measurement of γHV68 Infection in Mice

Published on: November 22, 2011

13.7K
Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
06:03

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

1.4K

Related Experiment Videos

Last Updated: Aug 18, 2025

Humanized NOD/SCID/IL2r&#947;null (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

15.8K
Measurement of &#947;HV68 Infection in Mice
13:22

Measurement of γHV68 Infection in Mice

Published on: November 22, 2011

13.7K
Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
06:03

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

1.4K

Area of Science:

  • Virology
  • Immunology
  • Hematology

Background:

  • Human Herpes Virus type 6 (HHV 6) can cause severe infections in immunocompromised individuals.
  • HHV 6 has the potential for genomic integration, complicating diagnostic differentiation between latent and active infection.
  • Limited data exists on HHV 6 viral interference, particularly in patients with hematological malignancies.

Purpose of the Study:

  • To identify laboratory markers for HHV 6 infection.
  • To determine the form of HHV 6 infection in patients with hematological malignancies.
  • To investigate HHV 6 viral interference with other herpesviruses in this patient group.

Main Methods:

  • Analysis of 98 patients with hematological malignancies and HHV 6 DNA.
  • Quantification of viral load in leukocytes and plasma.
  • Assessment of antiviral M and G immunoglobulins.
  • Evaluation of peripheral blood leukocyte counts.

Main Results:

  • Latent HHV 6 was detected in 67.3% of patients.
  • No integrated HHV 6 was confirmed, despite high viral loads in two cases.
  • Active HHV 6 infection was predominantly monoinfection (62.5%), with HCMV being the most common co-infectant (75% of mixed infections).
  • Mild leukopenia was observed during active HHV 6 infection.

Conclusions:

  • Latent HHV 6 is prevalent in patients with hematological malignancies.
  • Active HHV 6 infections are typically monoinfections, with HCMV as the most frequent co-infectant.
  • Integrated HHV 6 was not observed; active HHV 6 infection is associated with mild leukopenia and lower viral loads in mixed infections.